What are Crestor sales projections for 2025 through 2029? The projections below distinguish between Crestor-branded revenue and the broader global rosuvastatin market. Public-company reporting does not provide a reliable standalone current revenue series for Crestor in every geography. AstraZeneca revenue from Nexium by region 2018-2025 Leading antacid tablet brands in the U.S. 2019, based on sales Sales value of major prescription drugs Japan 2024 Revenue of AstraZeneca's product Crestor from 2018 to 2025, by region (in million U.S. dollars) AstraZeneca revenue from Crestor 2018-2025, by region Annual Sales of Crestor reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. 1 December 2020 07:00 GMT AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the UK and Spain, to Grünenthal GmbH (Grünenthal). Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia. Annual pharmaceutical drug sales This is a list of annual sales of patented medications per pharmaceutical group. Because it derives from 10-K data, drugs that have passed loss of exclusivity (LOE) will cease to be on this list. AstraZeneca said on Tuesday it would sell rights to its erstwhile blockbuster cholesterol drug, Crestor, to German pharmaceutical company Gruenenthal GmbH for an upfront payment of $320 million as … Figure 4 exhibits impressive rosuvastatin (Crestor®) use despite multiple statins being available as generics. These two examples clearly indicate that lack of blockbuster status of Brilinta® is … The drug has consistently had annual sales in the $5 to $6 billion range for the last several years. While there remains one, albiet infrequently prescribed, brand-name statin available in the US, the shift from Crestor to generic rosuvastatin marks the end of aggressively marketed statins competing for space in a crowded field. Aachen, Germany, 1 December 2020 Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced that it has agreed to acquire the European rights (excluding Spain and the UK) to CRESTOR™ (rosuvastatin) and its associated brands for a total consideration of up to US$ 350 million. Provides prescribing information for Crestor, including medication guide and instructions for use. CRESTOR is an HMG Co-A reductase inhibitor indicated for: adult patients with primary hyperlipidemia and mixed dyslipidemia as an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and TG levels and to increase HDL-C (1.1) pediatric patients 8 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total-C, LDL-C and ApoB after failing an … This report presents graphs and tables about some of AstraZeneca's top brands, Crestor and Nexium, but also of the drugs' generic versions. It provides key product figures, rankings, price … The drugmaker hopes to shrug off the pain of Crestor patent expirations in Europe and Japan in the second half of 2018. During the quarter, Crestor brought in $389 million in sales, declining 38% … AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany's Grunenthal. Crestor is a statin and at its peak generated annual revenues of more than $7 … Compare prices and print coupons for Crestor and other drugs at CVS, Walgreens, and other pharmacies. Prices start at $12.15 U.S. doctors are writing more prescriptions for AstraZeneca Plc's <AZN.L> cholesterol drug Crestor, following positive clinical trial results with the medicine released earlier this month. Shionogi said on June 1 that it will end the sale of the cholesterol drug Crestor (rosuvastatin) "due to various circumstances." This will make AstraZeneca, the marketing authorization holder, the sole marketer of the product. The Osaka drug maker announced… The document analyzes the sales and market status of the drug Crestor over a decade, illustrating its progression through the Boston Consulting Group matrix from a 'question mark' to 'cash cow' and finally to 'dog' status due to increasing generic competition and concerns about associated health risks. Crestor's sales peaked in 2011 but have since experienced a decline due to generics entering … Transfer your prescription for ROSUVASTATIN 20 MG TAB on Amazon Pharmacy. FREE SHIPPING for Prime members. Transfer your prescription for CRESTOR 20 MG TAB on Amazon Pharmacy. FREE SHIPPING for Prime members. AstraZeneca saw its Japan sales of the cholesterol fighter Crestor (rosuvastatin) in January-June plummet 71% year on year (72% on a constant exchange rate basis), dragged down by generic debuts in the second half of 2017. In the first half… Compare Crestor prices, print discount coupons, find manufacturer promotions, copay cards and patient assistance programs. Checking your browser before accessing pmc.ncbi.nlm.nih.gov … Rosuvastatin (Crestor) is an inexpensive drug used to lower cholesterol levels. It is slightly less popular than other statins. It is available in brand and generic versions. Generic rosuvastatin is covered by most Medicare and insurance plans, but some pharmacy coupons or cash prices may be lower. With the Patient Assistance Program from PAN Foundation, contact the program to see how they can … What are the latest 2025 news updates on Crestor (rosuvastatin) sales? The most recent, reliable "latest news" angle for Crestor sales in 2025 typically comes from company financial filings (by AstraZeneca, where applicable for branded markets) and from independent industry trackers that report prescriptions, retail share, or branded … The region also sits inside AstraZeneca's emerging-markets reporting, where Crestor sales grew to USD 934 million in 2024 from USD 862 million in 2023, a sign that the originator still sells well where generic substitution is less entrenched. Cardiovascular screening programmes add new patients each year. Global Rosuvastatin market share by region. Rosuvastatin Calcium or Crestor Savings, Coupons and Information. | ROSUVASTATIN (roe SOO va sta tin) treats high cholesterol and reduces the risk of heart attack and stroke. It works by decreasing bad cholesterol and fats (such as LDL, triglycerides) and increasing good cholesterol (HDL) in your blood. Wondering when a generic version of Crestor will be available? Get details on FDA approval status, generic manufacturers, and patent expirations. Rosuvastatin belongs to a group of drugs known as "statins." Rosuvastatin is available under the brand name "Crestor." Under the brand name of Crestor, Rosuvastatin is a lipid-lowering blockbuster drug in the world with a sales value of over USD 6 billion in 2012. Along with proper diet and exercise, Rosuvastatin Statin can decrease low-density lipoproteins (LDL), also known as bad … Compare generic Crestor (rosuvastatin calcium) 10 mg prices from verified online pharmacies or local U.S. pharmacies. Free coupons for generic Crestor (rosuvastatin calcium). Discounts up to 80% off the retail price. Compare Crestor 20 mg prices from verified online pharmacies or local U.S. pharmacies. Free coupons for Crestor. Discounts up to 80% off the retail price. Save on Rosuvastatin prescription medication with Blink Pharmacy. Same pills. Lower prices. No coupon req. CRESTOR is an HMG Co-A reductase inhibitor indicated for: adult patients with primary hyperlipidemia and mixed dyslipidemia as an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and TG levels and to increase HDL-C (1.1) pediatric patients 8 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total-C, LDL-C and ApoB after failing an … Crestor sale trends between 2003 and 2017 are presented in Fig. 4.2 and include the sales of Crestor by AstraZeneca, the sales of Crestor by Shionogi, and the patent royalties earned by Shionogi from the AstraZeneca sales of Crestor. Of note, global net sales reached more than 7 billion USD in 2011. The company reports that annual Crestor® brand sales in Canada are over $700 million and generic Rosuvastatin represents the second largest generic product launch in this market to date. The launch of Apo-Rosuvastatin comes years before the last Crestor® patents are set to expire, in August 2020. Crestor sale trends between 2003 and 2017 are presented in Fig. 4.2 and include the sales of Crestor by AstraZeneca, the sales of Crestor by Shionogi, and the patent royalties earned by Shionogi from the AstraZeneca sales of Crestor. ROSUVASTATIN (roe SOO va sta tin) treats high cholesterol and reduces the risk of heart attack and stroke. It works by decreasing bad cholesterol and fats (such as LDL, triglycerides) and increasing good cholesterol (HDL) in your blood. It belongs to a group of medications called statins. Changes to diet and exercise are often combined with this medication.